IN-A001
IN-A001 Uses, Dosage, Side Effects, Food Interaction and all others data.
IN-A001 (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. IN-A001’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. It has also been observed to be efficacious independent of food intake.
| Trade Name | IN-A001 |
| Generic | Tegoprazan |
| Tegoprazan Other Names | CJ-12420, IN-A001, K-CAB, LXI-15028, RQ-00000004, Tegoprazan |
| Type | |
| Formula | C20H19F2N3O3 |
| Weight | Average: 387.387 Monoisotopic: 387.13944781 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How IN-A001 works
IN-A001 works as a potassium-competitive acid blocker that is potent and highly selective. Its mechanism of action is different from that of the proton-pump inhibitors as this drug does not require conversion into an active form and can directly inhibit H+/K+‐ATPase in a reversible and K+‐competitive way. This is because it is an acid-resistant weak base with the ability to remain in the highly acidic canaliculi of gastric parietal cells.
Innovators Monograph
You find simplified version here IN-A001
